肺癌联合治疗方法的重大进展

摘要

在2014年，随着理解涉及肺癌患者的抗靶向药物逃离信号通路的进展，导致了应对抗靶向药物治疗路径的改进。厄洛替尼治疗，新的联合用药疗法，药物基因组驱动的个性化铂类药物化疗，以及应用PET评估，这些方法的潜在价值代表了另一项关键的重大进展。%With understanding involving the lung cancer resistance to targeted drugs related to escape the signaling pathways,the progress should be lead to the improvement anti-targeted drugs treatment path in 2014.For lung cancer treatment,new combination therapy and chemotherapy drug based on genome-driven personalized platinum drugs, how to manage the potential value of these drugs usage for PET therapy represents another key progress.